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Abstract Increased life expectancy is associated with aging
populations in the developed countries, and we can expect an
increased incidence of cardiovascular and inflammatory diseases
and cancers. A priority for medical research is to reduce such
morbidity. Leeches have been demonstrated to be a useful source
of drugs to treat cardiovascular diseases, as they have evolved
highly specific mechanisms to feed on their hosts by blocking
blood coagulation. Powerful molecules acting at different points
in the coagulation cascade or in the inhibition of platelet
aggregation have been purified from these animals. Moreover,
clinical trials confirm their potential to treat cardiovascular
diseases. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Animals depending on a diet of fresh blood have evolved
mechanisms that interfere with the coagulation process of the
blood donor. Normally, a nociceptive stress due to injury will
lead to an in£ammatory response with a large number of
leucocytes. It is in the leech’s interest to avoid this, as during
the months used to digest the blood meal the leucocytes will
release blood-degrading enzymes. Thus, the challenge for the
leech is to block peripheral nociception during the bite, to
reduce local in£ammation, and to synthesize anticoagulants
that maintain the blood in a £uid state during intake and
subsequent digestion [1]. In this regard, a variety of coagula-
tion inhibitors has been isolated from blood-sucking animals
such as bats [2], ticks [3,4], leeches [1,5], and hookworms [6].
Here we review the array of anticoagulant molecules and
platelet aggregation inhibitors derived from leeches: their
therapeutic uses and clinical trials.
2. Coagulation factor inhibitors
Among the di¡erent anticoagulant molecules in leeches in-
volved in the inhibition of the coagulation cascade or in inhi-
bition of the platelet aggregation (Fig. 1), three substances
have been investigated in detail. These are hirudin, a thrombin
inhibitor [7], antistasin, a factor Xa inhibitor [8], and decorsin,
an antagonist of platelet membrane glycoprotein IIb-IIIa (Ta-
ble 1) [9]. Although the amino acid sequences and the inhib-
itory activity of these molecules di¡er, their three-dimensional
structures share the same conformational motif, correspond-
ing to leech antihemostatic protein (LAP: Cys-X6-12-Cys-X-
Cys-X3-6-Cys-X3-6-Cys8-14) [10]. Interestingly, their mecha-
nisms of action and the epitopes important for binding to
their respective targets are also distinct [10]. This demon-
strates the signi¢cance of diverse mechanisms in inhibiting
the coagulation process, as well as the evolution of slightly
di¡erent inhibitory processes.
2.1. Thrombin inhibitors
2.1.1. Hirudin. Because thrombin is a key enzyme in the
pathogenesis of acute coronary thrombosis, therapy with hep-
arin, an indirect thrombin inhibitor, has developed over the
last three decades. The direct anti-thrombins, such as hirudin,
have emerged since the studies of Markwardt in 1957 [7]. The
presence of hirudin in the salivary glands of the leech, Hirudo
medicinalis, was ¢rst discovered by Haycraft in 1884 [11]. Its
role as a potent anti-thrombotic drug was ¢rst investigated by
Shionoya in 1927 [12], and its structure was established in
1950.
Hirudin is a natural single-chain peptide of 65 residues with
three intra-chain disul¢de bridges and a sulfated tyrosine res-
idue [13^16]. its N-terminal part is globular and very compact
owing to the presence of the three disul¢de bridges. By con-
trast, numerous negatively charged amino acid residues con-
stitute its C-terminal part. Over 100 years after its discovery,
its cDNA was cloned and large-scale production of recombi-
nant hirudin (rH) has been achieved in Escherichia coli [17], in
the yeast Saccharomyces cerevisiae [18], and now from Acre-
monium chrysogenum [19]. Compared with low molecular
weight heparins (Table 2), hirudin is a strict tight binding
inhibitor of thrombin [20]. It does not need a co-factor for
its activity. Its development, pre-clinical evaluation and intro-
duction into clinical trials of its recombinant and analogue
forms were perfected only 10 years ago [21].
The complex formed between hirudin and thrombin in-
volves both the three N-terminal amino acid residues, which
bind near to the active site, and the C-terminal tail that binds
to the ¢brinogen binding site. Crystal structure studies have
allowed researchers to conclude that the last 10 amino acid
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residues of the C-terminal region (residues 55^65) react with
the anion binding exosite site of thrombin, which is an im-
portant region for ¢brinogen binding [22]. Residues 1^48 of
the N-terminal part are also important for hirudin’s action on
thrombin [22]. They interact with the catalytic site. These
types of interaction explain why hirudin only binds to throm-
bin and not to other serine proteases.
The development of direct thrombin inhibitors has ad-
vanced from the elucidation of hirudin’s structure to the de-
velopment of a recombinant equivalent protein (r-hirudin).
Increased interest in thrombin inhibitors is also prompted
by reports of heparin-induced thrombocytopenia (HIT type
II) using heparin, and the consequent need to treat patients
with alternative anticoagulant drugs. These agents produce a
direct anticoagulant response by targeting thrombin. In addi-
tion, these thrombin inhibitors also inhibit platelet activation
by amplifying the coagulation cascade by thrombin activation
of factors V and VIII [23^26]. rH has produced promising
results in patients with unstable angina [27]. In the series of
trials termed Global Use of Strategies to open Occluded Cor-
onary Arteries (GUSTO) IIb, studies on patients with unsta-
ble angina show that in vivo thrombin generation and activity
are reduced during intravenous infusion of rH. Moreover, two
clinical trials in the series Assess Strategies for Ischemic Syn-
dromes (OASIS), have shown that rH is superior to heparin in
preventing cardiovascular death, myocardial infarction (MI)
and refractory angina or acute MI without ST elevation
[28,29]. Desirudin, an rH used in the prevention and manage-
ment of thromboembolitic disease, binds directly and with
high a⁄nity to clot-bound and £uid-phase thrombin [30]. In
patients undergoing hip-replacement surgery, desirudin was
signi¢cantly more e¡ective in reducing the incidence of deep
vein thrombosis (DVT) than either un-fractionated or low
molecular weight heparin [30]. When rH was compared with
heparin, there was a signi¢cant decrease in the incidence of
death or non-fatal (re) infarction at 24 h in patients with acute
MI was reported in GUSTO IIb trials but not in the Throm-
bolysis and Thrombin Inhibition in Myocardial Infraction
(TIMI) 9B trial. Thus, it appears that rH is more e¡ective
than heparin in the prevention of DVT in patients undergoing
elective replacement [30]. By contrast, the role of rH is less
well established in the treatment of acute coronary syndrome
[30].
2.1.2. New molecules discovered. Besides hirudin [7], other
thrombin inhibitors have been isolated from leeches. These
include granulin-like peptide [31], bufrudin [32], theromin
Table 1
Clinical phases of molecules extracted from leeches
Products Activity Therapy target Clinical level Company
Eglin inhibitor of elastase/
chymotrypsin
emphysema; non-steroidal anti-
in£ammatory
gene cloned in E. coli, pre-clinical
development
CIBA/Geigy, Basel,
Switzerland
Gelin inhibitor of elastase/
chymotrypsin
gingivitis and periodontitis;
dermatitis; non-steroidal anti-
in£ammatory
clinical trials in humans for oral
application and for dermatis
EuroBioPharm, Ridderkerk,
The Netherlands
Ghilanten inhibitor of factor
Xa
anticoagulant, antimetastatic primary structure studies; evaluation in
animal metastatic models
Merrell Dow Research Inst.,
Cincinnati, OH, USA
Hementin ¢brinogenolytic
enzyme
inhibits platelet aggregation gene cloning; pre-clinical development Biopharm, Charleston, USA
Orgelase hyaluronic acid-
speci¢c hyaluronidase
MI; drug delivery; ophthalmology pre-clinical development; including ex
vivo studies for drug delivery through
human skin
Biopharm, UK
Hirudin thrombin inhibitor MI phase IV development Transgene, France
Fig. 1. Targets of leech anticoagulants on homeostasis: up to date from Markwardt. 1: Antistasin, ghilanthen, therosasin; 2: hirudin, haemen-
din, bufrudin, theromin; 3: calin, LAPP; 4: decorsin, ornatin; 5: hementin, destabilase; 6: hementerin.
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[33] and haemadin [34]. Haemadin and theromin are com-
pletely new thrombin inhibitors having no sequence homology
with any other inhibitory factor yet sequenced throughout the
animal kingdom. Haemadin has been isolated from the leech,
Haemadipsa sylvestris [34]. It is a peptide of 5 kDa and with a
Ki of 100 fM, less active than both hirudin (21 fM) and ther-
omin (12 fM).
The most potent inhibitor is theromin (Ki of 12 vs. 21 fM
for hirudin), which has been isolated from the gut leech
Theromyzon tessulatum [33]. This is a homodimer of 67 amino
acid residues, with 16 cysteines engaged in eight disul¢de
bridges. Compared with hirudin, both peptides are anionic
and rich in cysteine residues [33]. Theromin’s N-terminal se-
quence is highly anionic and its C-terminal part very compact,
owing to the 10 cysteine residues present there. Hirudin’s N-
terminal sequence interacts with the catalytic site of thrombin,
and amino acid residues 46^48 (PKP) are important for the
link between hirudin and thrombin [22]. The same sequence
has been found in haemadin [34] and in H. manillensis anti-
thrombin peptides [32]. These types of interactions explain
why hirudin only binds to thrombin and not to other serine
proteases. By contrast, theromin does not possess such a dra-
matic signature in its sequence. In fact, theromin has no sig-
ni¢cant sequence homology with any other animal thrombin
inhibitor so far isolated. However, if theromin, containing
about 24% cysteine residues, is compared with potentially
homologous inhibitors, there is moderate similarity to antista-
sin-type protease inhibitors. This concerns mainly cysteine
residues. However, considering the low level of general se-
quence identity between theromin and peptides of this family,
it is di⁄cult to claim theromin as a new member of the anti-
stasin-type family. However, sequence comparisons have been
carried out between theromin and four di¡erent serine pro-
tease inhibitors isolated from the leech T. tessulatum : cytin,
therin, therostasin, and tessulin [35^38]. This revealed that
two of the four, therostasin [38] and tessulin [35], have a
high degree of sequence identity with theromin (70 and
52%, respectively). Furthermore, if theromin is aligned with
these potentially homologous inhibitors, the three proteins
show identity from residues 2 to 28, with the exception of
Val/Leu substitution at position 26 for theromin. The rest of
the sequences are less similar to each other. However, another
region is also well conserved between therostasin and thero-
min, namely a consensus sequence in residues 40^53 of ther-
omin (40DANGCESFCTCNTR53). Interestingly, the putative
active sites of the trypsin inhibitor, tessulin (25CLCKEPC31)
[36], and the factor Xa inhibitor, therostasin (33AQCRIYC39),
are not conserved in the thrombin inhibitor, theromin [33].
Thus, the observed similarities could be the result of an evolu-
tionary divergence from an ancestral gene, arising after gene
duplication, able to generate several peptides acting towards
speci¢c substrates. We can also add to the above Theromyzon
molecules the three other thrombin inhibitors discovered in
Theromyzon by Hamberger and collaborators (US patent
PCT/EP94/01404). In fact, the Merck Company 1994 depos-
ited foreign patent applications regarding three thrombin in-
hibitors of mass 3, 9 and 14 kDa. Interestingly, the N-terminal
sequence of the 9 kDa inhibitor, EDDNPGPPRACPGE (US
patent PCT/EP94/01404), shows homology with those of ther-
omin (ECENTECPRACPGE), the factor Xa inhibitor theros-
tasin (DCENTECPRACPGE) [38], and the trypsin inhibitor
tessulin (MCENTECPRACPGE) [36]. This 9 kDa thrombin
inhibitor peptide possesses a pI of 4.9, a clotting time in a
¢brinogen test of s 600 s/5 Wl, and a speci¢c activity at the
¢nal step of puri¢cation of 25 IU for thrombin inhibition and
0.2 IU for factor Xa inhibition. Clotting ¢brinogen assays
performed on di¡erent species of Theromyzon (T. binannula-
tum, T. cooperi, T. garjaewi, T. maculosum and T. sexocula-
tum) con¢rm the presence of thrombin inhibitor(s) in these gut
leeches (US patent PCT/EP94/01404). Taken together, these
data reveal that Theromyzon possesses di¡erent isoforms of
thrombin inhibitor. However, the 9 kDa protease inhibitor
possesses thrombin and factor Xa inhibitory activities, and
when we compared its activity to the one we obtained for
theromin, we observed that it is not a tightly binding inhibitor
for thrombin (US patent PCT/EP94/01404). We suspect that
this molecule might be a more speci¢c inhibitor of another
protease. Interestingly, theromin signi¢cantly diminishes the
level of human granulocyte and monocyte activation induced
by lipopolysaccharides (LPS) in a dose-dependent manner (1
U/ml). Moreover, in contrast to hirudin, which at concentra-
tions from 0.1 to 2 WM induced vasodilatation of PGF2 K-
precontracted ring segments of porcine pulmonary arteries
with intact endothelium, theromin has no e¡ect on human
saphenous vein endothelial cells [33]. Taken together, these
recent data indicate that these new leech thrombin inhibitors
still o¡er prospects for future development of practical appli-
cations.
2.2. Factor Xa inhibitors
The complementary roles of platelets and thrombin in the
pathophysiology of acute coronary syndromes suggest that,
Table 2
Comparison of some properties of hirudin with low molecular weight heparins
Hirudin Low molecular weight heparins
Speci¢c and potent inhibitor of thrombin Inhibits mainly factor Xa and much less factor IXa and
Xia
Anti-thrombin III-independent Anti-thrombin III-dependent
Not neutralized by heparinase, endothelium macrophages, ¢brin monomer,
plasma protein, platelet activator 4, neutral endopeptidase
Neutralized by heparinase, weak endothelium binding
Inactivates clot-bound thrombin Does not inactivate clot-bound thrombin and factor VII
Prevents thrombin-induced aggregation but not other platelet agonist Inhibits platelet function
Does not induce thrombocytopenia Can induce thrombocytopenia
Good bioavailability (80% after subcutaneous injection) Bioavailability after subcutaneous injection is s 90%
Fair dose^e¡ect response Fair dose^e¡ect response
Not immunogenic Not immunogenic
No liver toxicity Transient increase of liver enzymes is possible
No increase in vascular permeability No increase in vascular permeability
FEBS 24655 9-3-01
M. Salzet/FEBS Letters 492 (2001) 187^192 189
for treatment to be e¡ective, both mediators must be targeted
[39]. The direct utilization of factor Xa inhibitors is also a
promising route for anti-thrombotic therapy [39].
2.2.1. The antistasin protein. The ¢rst factor Xa inhibitor
found in leeches was antistasin, a 15 kDa protein isolated
from the salivary glands of the Mexican leech, Haementeria
o⁄cinalis [40]. A homologous protein, ghilanthen, has also
been found in Haementeria ghiliani [41]. Antistasin consists
of 119 amino acid residues, of which residues 1^55 (domain
I) are 56% similar to residues (56^110) (domain II). Of the
nine C-terminal amino acids (111^119; domain III), four are
positively charged [40]. The reactive site is located in domain I
[41^43]. The cDNA has been cloned [42], and the recombinant
protein has been produced in an insect baculovirus host vector
system [43]. Pharmaceutical studies have been performed, and
the data show that the protein is still active 30 h after injec-
tion in animals. Moreover, when tested in di¡erent thrombo-
sis models, antistasin was superior to heparin [44]. For exam-
ple; recombinant antistasin (rA) has been shown to reduce re-
stenosis after balloon angioplasty of atherosclerotic femoral
arteries in rabbits [44]. Moreover, chimeric peptides with only
domain I have been tested [40]. Neither domain II nor III
contain any intrinsic factor Xa inhibitory activity, nor do
they contribute to the activity of domain I. The most potent
synthetic peptide derived from antistasin corresponds to ami-
no acids 27^49 with a disul¢de bridge (ATS29^47). This in-
hibited factor Xa with a Ki of 35 nM [45]. The shortest pep-
tide displaying anticoagulant activity was D-RCRVHCP,
which increased clotting times by 50% at micromolar concen-
trations [45]. Based on these results and the understanding of
the molecular mechanisms implicated in factor Xa inhibition,
new anticoagulants have been produced (e.g. DX-9065a) [46].
Tolerability, pharmacokinetic and pharmacodynamic studies
of DX-9065a have demonstrated that this synthetic inhibitor
has a good correlation between linear pharmacokinetics and
pharmacodynamics after intravenous administration in hu-
mans [47]. In vitro characterization of RPR130737, a novel
synthetic factor Xa inhibitor, showed a selectivity of 1000-fold
over thrombin in terms of activated protein C, plasmin, tissue-
plasminogen partial thromboplastin time, and prothrombin
time in a dose-dependent fashion [47].
As well as antistasin, we also isolated therostasin from T.
tessulatum. This is a potent naturally occurring tight binding
inhibitor of mammalian factor Xa (Ki 34 pM) [38]. Therosta-
sin is a cysteine-rich protein consisting of 82 amino acid res-
idues with 16 cysteine residues. Sequence analysis reveals that
Table 3
Comparison of active site sequences of antistasin-type protease inhibitor
P4 P3 P2 P1 P1P P2P P3P Inhibitors of Reference
Antistasin I V R C R I H C factor Xa, trypsin [40]
Antistasin II I N C R K T C factor Xa, trypsin [40]
Ghilanten V R C R V Y C factor Xa, trypsin [41]
Guamerin I I R C M I F C elastase [62]
Guamerin II I R C M I F C chymotrypsin [63]
Hirustasin V H C R I R C cathepsin G, trypsin [64]
Tessulin C L C K E P C chymotrypsin, trypsin [37]
Therin Y L C K M A C trypsin [35]
Therostasin A Q C R I Y C factor Xa [38]
Table 4
Molecules isolated from leeches and implicated in inhibition of the coagulation cascade or in the inhibition of platelet aggregation
Species Molecule Biological action Type of leech Reference
H. medicinalis calin platelet aggregating inhibitor factor jawed [51]
bdellins trypsin and plasmin inhibitors jawed [65]
bdellastasin trypsin and plasmin inhibitor jawed [66]
destabilase ¢brin de-polymerase factor jawed [57]
LDTI tryptase, trypsin, chymotrypsin jawed [67]
hirudin inhibitor jawed [13]
hirustasin thrombin inhibitor trypsin, chymotrypsin, cathepsin G, kallikrein inhibitor jawed [64]
Hirudo nipponia granulin thrombin inhibitor jawed [31]
guamerin I elastase inhibitor jawed [62]
piguamerin trypsin and kallikrein inhibitor jawed [68]
Hirudinaria manillensis bufrudin thrombin inhibitor jawed [32]
gelin elastase, cathepsin G, chymotrypsin, subtilisin inhibitor jawed [69]
H. sylvestris haemadin thrombin inhibitor jawed [34]
Whitmania endulata guamerin II elastase, chymotrypsin inhibitor jawed [63]
Macrobdella decora decorsin GPIIb/IIIa inhibitor jawed [9,55]
H. o⁄cinalis antistasin factor Xa inhibitor proboscis [40]
LAPP platelet aggregating inhibitor factor proboscis [56]
H. ghilianii ghilanten factor Xa inhibitor proboscis [41]
hementin ¢brinolytic enzyme proboscis [70]
Haementeria lutzi hementerin ¢brigenolytic enzyme proboscis [60]
Placobdella ornata ornatin GPIIb/IIIa inhibitor proboscis [56]
T. tessulatum cytin chymotrypsin inhibitor proboscis [37]
tessulin trypsin, chymotrypsin inhibitor proboscis [36]
therin trypsin inhibitor proboscis [35]
theromin thrombin inhibitor proboscis [33]
therostasin factor Xa inhibitor proboscis [38]
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therostasin is completely novel. Its cDNA (825 bp) encodes a
polypeptide of 82 amino acid residues preceded by 19 residues
representing a signal peptide sequence. As with the other
known inhibitors of factor Xa, therostasin is expressed and
stored in cells of the leech salivary glands [38]. This peptide is
also di¡erent from the factor Xa inhibitor isolated from Hae-
menteria depressa, lefaxin [48]. Amidolytic activity of lefaxin
on chromogenin substrate revealed an apparent Ki of 4 nM.
This protein, of 30 kDa with an isoelectric point of 5.7, has
sequence similarity with the nitric oxide carrier protein myo-
hemerythrin from the annelid Nereis diversicolor [49].
2.2.2. Antistasin-type molecules. The P1 residue in serine
protease inhibitors most often re£ects the speci¢city of the
proteinase that is being inhibited; i.e. lysine or arginine resi-
dues for trypsin-like enzymes and phenylalanine and leucine
for chymotrypsin-like enzymes [50]. For factor Xa inhibitor,
P1 is often an arginine-like residue, as in antistasin and ghi-
lanthen. Based on these considerations and because several
molecules have the same-spacing in the 10 cysteine residues,
a novel family has been de¢ned: the antistasin-type family
(Table 3). Molecules of this family display di¡erent activities
towards serine proteases, and it appears that the major di¡er-
ences in speci¢city are caused by di¡erences in the sequence
surrounding the reactive site (Table 3). Moreover, some of the
molecules of this family, such as therin and tessulin, show
anti-in£ammatory activity, [35,36]. Experiments conducted
with LPS to mimic a septic injury show that LPS stimulates
immunocytes in a process that exhibits primary and secondary
levels of stimulation. The LPS-stimulated secondary e¡ect re-
quires enzyme-processed secretory products released from the
immunocytes [35,36]. Therin, tessulin or therostasin applied
alone diminish the immunocyte activation level ; administered
in combination they act synergistically. This indicates that
they also exert an enzyme-inhibitory action on in£ammation.
They might have a high medical interest as therapeutic agents
to curtail emphysema, cancer and in£ammation.
2.3. Molecules acting on a di¡erent point of the coagulation
cascade or on platelet aggregation inhibition
In addition to the targets discussed above (thrombin and
factor Xa), leeches have developed an arsenal of highly spe-
ci¢c and powerful weapons acting at di¡erent steps of the
coagulation cascade, on the ¢brinolysis pathway, and on
platelet aggregation and activation (Fig. 1, Table 4).
Calin (isolated from H. medicinalis) speci¢cally blocks ad-
hesion and aggregation of platelets induced by collagen [51].
Calin induces an anti-thrombotic e¡ect in a thrombosis model
rich in platelets [52]. Similarly, in proboscis leeches, a protein
of 126 amino acid residues, termed the leech antiplatelet pro-
tein (LAPP), has been discovered in H. o⁄cinalis [53]. The use
of the recombinant protein in sections of human arterioscler-
otic coronary arteries blocked platelet aggregation [54]. How-
ever, direct injection of LAPP to baboons did not prevent the
experimental development of thrombi [55].
Decorsin [56] and ornatin [57] are two powerful antagonists
of the GPIIb/IIIa protein. By their RGD sequence, these pep-
tides are inhibitors of platelet aggregation by being compet-
itors of the GPIIb/IIIa for its receptor on the platelets. Tri-
degin, a factor XIIIa inhibitor, has also been isolated from H.
ghilianii [58].
Leeches have also developed molecules able either to cleave
¢brin cross-links, such as destabilase [59] or the ¢brinogeno-
lytic-enzyme-like hementin [60]. Hementin inhibits platelet ag-
gregation by destroying the ¢brinogen necessary to aggregate
them. Moreover, this enzyme is also able to disaggregate
platelets once they have aggregated by destroying the ¢brin-
ogen that links the platelets together. By contrast, hementerin
[61] is able to activate the ¢brinolytic human plasma system in
presence of a serum co-factor and calcium. This molecule dis-
plays similarity with streptokinase.
3. Conclusions
Taken together, this overview demonstrates that leeches
have developed a panoply of molecules that interfere with
the coagulation cascade and platelet activation. Leeches are
a valuable reservoir of new powerful natural peptides to treat
in£ammation, coagulation, thrombosis, emphysema, and can-
cer, which are all diseases of aging.
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